Study on Chemotherapy With or Without Ganitumab for Newly Diagnosed Metastatic Ewing Sarcoma

Program Overview

The purpose of this study is to determine if adding ganitumab, a drug that blocks a pathway important for tumor growth, to standard chemotherapy can help treat Ewing sarcoma that has spread. Standard chemotherapy includes drugs like vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide, which work by killing cancer cells or stopping them from growing and spreading. Researchers want to find out if the combination of ganitumab and chemotherapy is more effective than chemotherapy alone.

Description

The main goal of this study is to see if adding ganitumab to standard chemotherapy improves the time patients live without the cancer getting worse. Researchers will also look at the side effects of adding ganitumab and compare overall survival rates between those who receive ganitumab and those who do not.

The study will also explore how well the cancer responds in the bone marrow and the effects of ganitumab as a maintenance therapy after initial treatment. Researchers will examine various biological markers to see if they affect treatment outcomes.

Participants are randomly assigned to one of two treatment groups. One group receives standard chemotherapy, while the other group receives standard chemotherapy plus ganitumab. Both groups undergo surgery and/or radiation therapy as part of their treatment. After completing the study treatment, participants are followed for 10 years to monitor their health and any long-term effects.

Eligibility Criteria

Locations